Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer

NCT ID: NCT00791141

Last Updated: 2014-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-08-31
• Study Completion Date: 2013-09-30

Brief Summary

This multicenter, open-label, uncontrolled phase II trial evaluates safety and efficacy of post-operative chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck.

Detailed Description

Advanced squamous cell carcinoma of the head and neck still has a poor prognosis and loco-regional recurrence frequently occurs. Efforts have been made to improve response rates and survival and different therapeutic regimens including concurrent chemo-radiotherapy or sequential chemo-radiotherapy have been developed.

To further increase the outcome of patients with locally advanced SCCHN effective new treatments with minimal toxicities are needed. Molecular targeted agents, which do not demonstrate overlapping toxicities with commonly used chemotherapy agents, have therefore been investigated. The EGFR is widely expressed at high levels in SSCHN and is associated with poor prognosis.

Cetuximab has already been investigated in combination with radiotherapy or chemotherapy in patients with head and neck cancer. The immunoradiotherapy was well tolerated with most of the side effects related to the high dose irradiation. The most common side effects are mucositis and dysphagia. Additionally, skin reactions appear sometimes more frequently in cetuximab administration. Grade 3 to 4 infusion reactions were observed in 3% of the patients treated with cetuximab. Based on the current promising results with RCT in patients with locally advanced head and neck cancer and clinical results with EGFR-antibodies plus RT, the present study was primarily designed to define the acute grade 3/4 toxicity.

We expect to show effective results in reducing the risk of distant metastasis, with administration of an additional six month adjuvant cetuximab treatment, in patient with recurrent SCCHN.

Conditions

Head and Neck Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cetuximab

Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.

Group Type: EXPERIMENTAL

Cetuximab

Intervention Type: DRUG

Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.

Interventions

Cetuximab

Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.

Intervention Type: DRUG

Other Intervention Names

Erbitux

Eligibility Criteria

Inclusion Criteria

• Signed written informed consent;
• Males or females between 18 and 70 years of age;
• Surgically resected squamous cell carcinomas of the hypopharynx, oropharynx, larynx and oral cavity with high risk of locoregional recurrence not more than 6-9 weeks (maximum) ago;
• To be categorized as high risk patients have to fulfil at least one of the following criteria:

• R0 - resection <5 mm margin
• R1 - resection
• Extracapsular nodal extension;
• no previous chemotherapy, radiotherapy;
• Performance status ECOG: 0 - 1;
• Contraception in male and female patients if of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing;
• Adequate renal, liver and hematological functions (within maximum 9 weeks until surgery):

• Adequate bone marrow function: neutrophils > 1.5 x 10^9/L, platelets > 100 x 10^9/L, hemoglobin > 10.0 g/dL
• Adequate liver function: Bilirubin < 2.0 mg/dL, AST, ALT, AP, γ-GT < 3 x ULN
• Adequate renal function: creatinine clearance > =60 ml/min
• No distant metastases;

Exclusion Criteria

• Nasopharyngeal carcinoma;
• R2 resection;
• Invalid informed consent;
• Performance Status > 1;
• Previous chemotherapy or radiotherapy for carcinoma of the head and neck;
• Prior exposure to EGFR pathway targeting therapy;
• Other serious illness or medical conditions:

• Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4;
• Clinically significantly abnormal electrocardiogram (ECG) or left ventricular ejection fraction (LVEF) below the institutional range of the normal
• Significant neurologic or psychiatric disorders including dementia or seizures;
• Active uncontrolled infection;
• Active disseminated intravascular coagulation;
• Other serious underlying medical conditions which could impair the ability of the patient to participate in the study;
• Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC v3.0) grade 2 or ototoxicity grade 2, except if due to trauma or mechanical impairment due to tumor mass;
• Having participated in another therapeutic clinical trial or any investigational agent in the preceding 30 days;
• Known allergic/hypersensitivity reaction to any of the components of the treatment;
• Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding;
• Known drug abuse;
• Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;
• Legal incapacity or limited legal capacity;
• Sensitivity and incompatibility against 5-Fluorouracil
• Sensitivity and incompatibility against platinum-compounds
• Known incompatibilities >grade 3 towards cetuximab
• expected incompliance of patient (e.g. in case of severe alcohol addiction)
• Dental evaluation: Pre treatment dental care before start of radiochemotherapy (approximately 8 to 10 days lapse-time is needed for complete recovery before initiation of radiation therapy).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Heinrich-Heine University, Duesseldorf

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wilfried Budach, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Department of Radiotherapy and Radiological Oncology

Locations

Department of Radiotherapeutics of the University Hospital Freiburg

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Department of Radiological Oncology University Hospital Heidelberg

Heidelberg, Baden-Wurttemberg, Germany

Department of Radiotherapy and Radiological Oncology University Hospital Tuebingen

Tübingen, Baden-Wurttemberg, Germany

Department of Radiotherapy and Radiological Oncology University Hospital Ulm

Ulm, Baden-Wurttemberg, Germany

Department of Radiotherapy and Radiological Oncology, University Hospital Munich

Munich, Bavaria, Germany

Department of Radiotherapy an Radiological Oncology University Hospital Essen

Essen, North Rhine-Westphalia, Germany

Department of Radiotherapy and Radiological Oncology University Hospital Mainz

Mainz, Rhineland-Palatinate, Germany

Department of Radiotherapy, University Hospital Schleswig Holstein, Campus Lübeck

Lübeck, Schleswig Hostein, Germany

Charité University Medicine, Department of Radiotherapy and Radiological Oncology

Berlin, State of Berlin, Germany

Department of Radiotherapy and Radiological Oncology Universität Hospital Jena

Jena, Thuringia, Germany

Countries

Germany

References

Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007 Aug 2;357(5):514-5. doi: 10.1056/NEJMc071075. No abstract available.

Reference Type: BACKGROUND

PMID: 17671265 (View on PubMed)

Other Identifiers

ACCRA-HN

Identifier Type: -

Identifier Source: org_study_id